US pharma company Pfizer has launched China's first pay-for-performance insurance product, with breast cancer drug Ibrance palbociclib, in partnership with PICC Health Insurance and Shanghai MediTrust Health. The programme is being rolled out in 34 cities, and is available to a maximum of 500 patients with no previous first-line endocrine therapy treatment. In China, the government has been trying for years to encourage women to undergo hormone replacement therapy, which can cost up to $US50,000 per year.
US pharma company Pfizer has launched China's first pay-for-performance insurance product, with breast cancer drug Ibrance palbociclib, in partnership with PICC Health Insurance and Shanghai MediTrust Health. The programme is being rolled out in 34 cities, and is available to a maximum of 500 patients with no previous first-line endocrine therapy treatment. Pfizer said those experiencing disease progression or metastasis within the first 126 days of beginning Ibrance treatment, or in combination with an aromatase inhibitor, will be reimbursed with up to 33.5% of the cost.